高级检索
当前位置: 首页 > 详情页

Insulin Resistance and the Prognosis in Diffuse Large B-cell Lymphoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hebei Tumor Hosp, Dept Endocrine & Metab Dis, Hosp 4, Shijiazhuang, Hebei, Peoples R China [2]Hebei Med Univ, Hebei Tumor Hosp, Dept Hematol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
出处:
ISSN:

关键词: Insulin resistance Diffuse large B-cell lymphoma Overall survival Prognosis

摘要:
Objective: To investigate whether insulin resistance (IR) affects the prognosis in patients with diffuse large B-cell lymphoma (DLBCL).Place and Duration of the Study: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, from September 2017 to December 2021.Methodology: This study retrospectively analysed 324 patients with DLBCL who were divided into a non-IR group (251 cases) and IR group (73 cases) according to IR. The authors collected clinical data of the study population and calculated the overall survival (OS) of patients through inpatient case data or follow-up. The Cox regression method was used to assess the prog-nostic factors of the patients. The Kaplan-Meier method was used for drawing the survival curve of IR on OS of the DLBCL patients.Results: The IR group had older age, higher international prognostic index (IPI), later stage, and higher insulin levels. The five-year OS rate was 46% in the IR group and 66% in the non-IR group. Compared with the non-IR group, the IR group showed a poor prognosis (OS: adjusted HR 1.23, 95% CI: 1.02-1.41, p = 0.031).Conclusion: IR was one of the factors leading to poor prognosis in patients with DLBCL, and attention should be paid to this risk factor.

基金:

基金编号: 20221232

语种:
WOS:
PubmedID:
中科院分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2023]版:
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q3 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hebei Tumor Hosp, Dept Endocrine & Metab Dis, Hosp 4, Shijiazhuang, Hebei, Peoples R China
通讯作者:
通讯机构: [1]Hebei Med Univ, Hebei Tumor Hosp, Dept Endocrine & Metab Dis, Hosp 4, Shijiazhuang, Hebei, Peoples R China [*1]Department of Endocrine and Metabolic Diseases, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital), Hebei, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39766 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号